The sirtuin 1 (SIRT1) inhibitor cambinol induces apoptosis and inhibits proliferation in multiple myeloma (MM) cell lines, according to research published in Oncology Letters.
MM accounts for about 10% to 15% of hematological malignancies. Despite advances in treatments that have improved survival, MM remains incurable. Research continues into novel therapeutics to overcome drug resistance.
Therapies that target histone deacetylases (HDACs) may induce apoptosis and stop disease progression. SIRT1 is known to contribute to the development of hematologic malignancies. SIRT1 inhibitors have been studied for antitumor activity in cells from solid tumors.
This study evaluated the effect of the SIRT1 inhibitor cambinol on MM cell lines RPM18226 and U266. In both cell lines, cambinol inhibited cell proliferation in a dose- and time-dependent manner.
The MM cell lines were compared to controls. RPM18226 cells treated with cambinol had an apoptotic rate of 55.72% compared to 11.43% in the control cells. Treated U266 cells had an apoptotic rate of 36.71% compared to 6.3% in the control cells.
Cambinol also induced cell-cycle arrest in both cell lines. A total of 39.73% of RPM18266 cells treated with cambinol for 48 hours were in the G1 phase. A total of 66.33% of drug-treated U266 cells were in the G1 phase at analysis.
RPM18226 cells and U266 cells were treated with cambinol in different concentrations. Results showed that cambinol decreased SIRT1 activity in a dose-dependent manner (P <.001).
The study authors concluded that the antitumor activity of cambinol is likely a result of apoptosis and cell-cycle arrest. The results suggested cambinol and its analogs may be promising treatments for MM.
Lu B, Zhang D, Wang X, Lin D, Chen Y, Xu X. Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells. Oncol Lett. 2021;21(4):306. doi:10.3892/ol.2021.12567
This article originally appeared on Hematology Advisor